이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

야간 교대 근무자에서 Akkermansia Muciniphila와 베르베린 보충이 인슐린 민감성에 미치는 영향 (Shift2Health)

2026년 11월 10일 업데이트: FH Joanneum Gesellschaft mbH

Shift2Health 프로젝트 내에서의 이중 맹검, 무작위, 위약 대조, 교차 연구: 야간 교대 근무자의 인슐린 감수성에 대한 Akkermansia Muciniphila 및 Berberine 보충의 효과

Night shift work is associated with an increased risk of obesity, insulin resistance, and cardiometabolic disorders, largely due to circadian misalignment, disrupted sleep, and altered eating patterns. These behavioral and physiological disturbances impair glucose metabolism and are further influenced by the gut microbiota. In particular, the bacterium Akkermansia muciniphila has been linked to improved metabolic health, including enhanced insulin sensitivity, lipid regulation, and maintenance of intestinal barrier integrity. Berberine, a bioactive plant-derived compound, has demonstrated metabolic benefits, including upregulation of A. muciniphila, improvement of insulin sensitivity, and modulation of lipid metabolism.

Together, these complementary mechanisms suggest that combined A. muciniphila supplementation and berberine administration may synergistically improve metabolic health in shift workers by targeting gut microbiota composition and circadian-regulated metabolic pathways.

Based on this rationale, a double-blind, randomized, placebo-controlled, crossover study is being conducted in 200 night-shift workers from healthcare and industrial sectors in Austria and Denmark. Participants are stratified by age, sex, and work sector and randomly assigned to intervention sequences. Each participant receives either the combined supplement or placebo for 12 weeks, followed by a four-week washout, after which the alternate intervention is administered for another 12 weeks, with a total participation of 28 weeks.

Assessments are performed at four study visits and include anthropometry, body composition, blood pressure, and collection of blood, urine, and feces. Participants complete validated questionnaires on dietary intake, lifestyle, work schedules, and general health to monitor behavioral patterns throughout the study. Dietary intake is recorded for four days prior to each sampling visit in consideration of shift schedules. Sleep duration and quality are monitored via diaries and actigraphy and aligned with dietary records. Circadian variation is minimized by standardizing sampling times and implementing a fasting and synchronization period prior to visits.

The primary outcome is insulin sensitivity, measured by HOMA-IR. Secondary exploratory outcomes include gut microbiota composition and diversity, biomarkers of intestinal permeability and inflammation, lipid profiles, body composition, sleep quality, and dietary behavior.

These measures collectively provide a comprehensive evaluation of the metabolic, microbiome, and circadian effects of combined A. muciniphila and berberine supplementation in night-shift workers.

연구 개요

상태

모병

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

200

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

21년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Health care or industrial shift worker
  • Employed or self-employed working ≥ 24 h/week
  • Current night shift work (night shift defined as a work schedule that includes at least 3 hours of work between 00:00 and 5:00) with at least 2 consecutive nights/month
  • Night shift work duration > 3 years
  • 4 or more night shifts/month

Exclusion Criteria:

  • BMI of 40 kg/m² or higher
  • Pregnancy or planned pregnancy within 6 months of enrolment or breastfeeding women
  • Bariatric surgery
  • Surgery in the 3 months prior to the study or planned surgery in the next 6 months that, in the opinion of the investigators, could potentially affect the outcome of the study
  • Diagnosed diabetes type 1 or type 2
  • Uncontrolled thyroid disease (confirmed by clinically significant abnormal TSH/T4 levels without stable medication for more than 3 months)
  • Chronic diseases (renal failure, active hepatitis, liver cirrhosis, myocardial infarction within the last 2 years, stroke, chronic obstructive pulmonary disease or cancer)
  • Immunodeficiency syndrome, active autoimmune or autoinflammatory disease (e.g. multiple sclerosis, lupus, rheumatoid arthritis), inflammatory bowel disease (e.g. IBS or ulcerative colitis) and acute episodes of atopic diseases (atopic dermatitis, asthma, type 1 allergies such as hay fever). Grave's disease, Hashimoto thyroiditis, Celiac disease, sarcoidosis, Lichen planus, are allowed, if well treated and stable
  • Regular intake of anticoagulants
  • Known allergy to any inactive or active ingredients in the study products
  • Participation in other clinical intervention trials during the study
  • Current or planned participation in a weight loss program (including intermittent fasting), extreme diet, or vigorous exercise (e.g., running, fast cycling, swimming laps, or playing intense sports that quickly raise your heart rate)

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 기초 과학
  • 할당: 무작위
  • 중재 모델: 크로스오버 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: AB Group

Participants will first receive Verum (A) for 3 months. After a 4-week washout period, they will receive Placebo (B) for 3 months.

1 capsule of A. muciniphila (pasteurized, initial quantity of 3x10^10 TFU, heat inactivated) and 1 capsule of 500 mg berberine hydrochloride per day.

1 capsule of A. muciniphila placebo and 1 capsule of berberine placebo (both identical to verum regarding the shape, size, colour, and matched in excipients) per day.

실험적: BA Group

Participants will first receive Placbo (B) for 3 months. After a 4-week washout period, they will receive Verum (A) for 3 months.

1 capsule of A. muciniphila (pasteurized, initial quantity of 3x10^10 TFU, heat inactivated) and 1 capsule of 500 mg berberine hydrochloride per day.

1 capsule of A. muciniphila placebo and 1 capsule of berberine placebo (both identical to verum regarding the shape, size, colour, and matched in excipients) per day.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change of 3-months supplementation with A. muciniphila and berberine on insulin resistance using HOMA-IR compared to placebo
기간: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

Homeostasis Model Assessment of Insulin Resistance, calculated as (fasting insulin (μU/ml) x fasting glucose (mmol/l)) / 22.5, will be assessed to calculate the change between baseline and endpoint in the two periods

At the beginning and the end of each intervention period (week 0, 12, 16, 28)

2차 결과 측정

결과 측정
측정값 설명
기간
Change in gut microbiom composition between the baseline and endpoint change in the two periods
기간: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

Gene sequencing of the 16S rRNA is performed on the stool samples to compare microbiota diversity and relative abundance

At the beginning and the end of each intervention period (week 0, 12, 16, 28)
Change in FABPi between the baseline and endpoint change in the two periods
기간: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

Measurement of FABP intestinal (FABPi) in blood (pg/mL)

At the beginning and the end of each intervention period (week 0, 12, 16, 28)
Change in zonulin between the baseline and endpoint change in the two periods
기간: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

Measurement of zonulin in blood (ng/mL)

At the beginning and the end of each intervention period (week 0, 12, 16, 28)
Change in LPB between the baseline and endpoint change in the two periods
기간: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

Measurement of lipopolysaccharide-binding protein (LPB) in blood (pg/mL)

At the beginning and the end of each intervention period (week 0, 12, 16, 28)
Change in CRP between the baseline and endpoint change in the two periods
기간: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

Analysis of high-sensitive C-reactive protein (hs-CRP, mg/L) in blood

At the beginning and the end of each intervention period (week 0, 12, 16, 28)
Change in stool short-chain fatty acids (SCFA) between the baseline and endpoint change in the two periods
기간: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

SCFA will be extracted and quantitatively analysed by GC-MS (µmol/g)

At the beginning and the end of each intervention period (week 0, 12, 16, 28)
Change in blood lipid profile and cardiovascular markers between the baseline and endpoint change in the two periods
기간: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

Measurement of cholesterol (mmol/L), low-density lipoprotein cholesterol (LDL-C, mmol/L), high-density lipoprotein (HDL-C, mmol/L), and triglyceride levels (TG, mmol/L) in blood

At the beginning and the end of each intervention period (week 0, 12, 16, 28)
Change in blood pressure between the baseline and endpoint change in the two periods
기간: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

Systolic BP (mmHG) and diastolic BP (mmHG)

At the beginning and the end of each intervention period (week 0, 12, 16, 28)
Change in melatonin between the baseline and endpoint change in the two periods
기간: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

6-sulfatoxymelatonin in urine (µg/L)

At the beginning and the end of each intervention period (week 0, 12, 16, 28)
Change in BMI between the baseline and endpoint change in the two periods
기간: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

Body mass index (BMI)

At the beginning and the end of each intervention period (week 0, 12, 16, 28)
Change in body composition between the baseline and endpoint change in the two periods
기간: At the beginning and the end of each intervention period (week 0, 12, 16, 28)

Bioelectrical Impedance Analysis (BIA)

At the beginning and the end of each intervention period (week 0, 12, 16, 28)
Change in metabolomics at the end of the two periods
기간: At the beginning and the end of each intervention period (week 12, week 28)

Metabolomic profiles obtained with LC-MS/MS

At the beginning and the end of each intervention period (week 12, week 28)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 1월 20일

기본 완료 (추정된)

2027년 10월 1일

연구 완료 (추정된)

2028년 2월 1일

연구 등록 날짜

최초 제출

2026년 1월 27일

QC 기준을 충족하는 최초 제출

2026년 2월 23일

처음 게시됨 (실제)

2026년 2월 27일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2026년 1월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 1306/2025
  • 101080788 (기타 보조금/기금 번호: Horizon Europe)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .